A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes

Clinical Transplantation

Volumn 11, Issue 5 II, 1997, Pages 522-528

  Tsuchida, Masanori ^a   Brown, Stephen A ^a   Tutt, Libby M ^a   Tan, Jian ^a   Seehafer, Darin L ^a   Harris, Jason P ^a   Xun, Chang Q ^a   Thompson, John S ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

Anti T cell monoclonal antibody; Human; PBL; SCID mice; Skin graft

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; OKT 3; T LYMPHOCYTE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSPLANTATION; GRAFT REJECTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MORTALITY; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SCID MOUSE; SKIN GRAFT; T LYMPHOCYTE; WHOLE BODY RADIATION;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; CELL DIVISION; CYTOKINES; DISEASE MODELS, ANIMAL; G(M1) GANGLIOSIDE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPOTHERMIA; IMMUNE SERA; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; MUROMONAB-CD3; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SKIN TRANSPLANTATION; SURVIVAL RATE; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS; WHOLE-BODY IRRADIATION;

EID: 0030813729     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. ALEGRE ML, PETERSON LJ, JEYARAJAH DR, WEISER M, BLUESTONE JA, THISTLETHWAITE JR. Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts. J Immunol 1994: 153: 2738.
2. ALGRE ML, PETERSON LJ, XU D, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994: 57: 1537.
3. SHIROKI R, POINDEXTER NJ, WOODLE ES, HUSSAIN MS, MOHANAKUMAR T, SCHARP DW. Human peripheral blood lymphocyte reconstituted severe combined immunodeficient (hu-PBL-SCID) mice. A model for human islet allograft rejection. Transplantation 1994: 57: 1555.
4. MACKENZIE DA, SOLLINGER HW, HULLETT DA. Acute graft rejection of human fetal pancreas allografts using donor-specific human peripheral blood lymphocytes in the SCID mouse. Transplantation 1996: 61: 1461.
5. MURRAY AG, PETZELBAUER P, HUGHES CCW, COSTA J, ASKENASE P, POBER JS. Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse. Proc Natl Acad Sci USA 1994: 91: 9146.
6. MI. J Immunol Methods 1994: 169: 1.
7. SANDHU J, SHPITZ B, GALLINGER S, HOZUMI N. Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes. J Immunol 1994: 152: 3806.
8. XUN CQ, THOMPSON JS, JENNINGS CD, BROWN SA. Effect of human IL-2 activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells. Transplantation 1995: 60: 821.
9. XUN CQ, TSUCHIDA M, THOMPSON JS. Delaying transplantation after total body irradiation is a simple and effective way to reduce acute graft-versus-host disease mortality after major H-2 incompatible transplantation. Transplantation 1997: 64: 297.
10. SALMERON A, SACCHEZ-MADRID F, URSA MA, FRESNO M, ALARCON B. A conformational epitope expressed upon association of CD3-ε with either CD3-γ or CD3-δ is the main target for recognition by anti-CD3 monoclonal antibodies. J Immunol 1991: 147: 3047.
11. WAID TH, LUCAS BA, AMLOT P, et al. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection. Am J Kidney Dis 1989: 24(5, Suppl. 2): 61.
12. WAID TW, LUCAS BA, THOMPSON JS, et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 1992: 53: 80.
13. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985: 313: 337.
14. LEO O, Foo M, SACHS DH, SAMELSON LE, BLUESTONE JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987: 84: 1374.
15. HIRSH R, ECKHAUS M, AUCHINCLOSS HJ, SACHS DH, BLUESTONE JA. Effects of In vivo administration of anti-T3 monoclonal antibody on T-cell function in mice. Immunosuppression of transplantation responses. J Immunol 1988: 140: 3766.
16. TARY-LEHMANN M, SAXON A. Human mature T cells that are anergic in vivo prevail in SCID mice reconstituted with human peripheral blood. J Exp Med 1992: 175: 503.
17. + T-cell repertoire in hu-PBL-SCID chimeras. J Exp Med 1994: 180: 1817.
18. ARMSTRONG N, CIGEL F, BORCHERDING W, HONG R, MALKOVSKA V. In vitro preactivated human T cells engraft in SCID mice and migrate to murine lymphoid tissues. Clin Exp Immunol 1992: 90: 476.
19. KAWAMURA T, NIGUMA T, FECHNER JH et al. Chronic human skin graft rejection in severe combined immunodeficient mice engrafted with human PBL from an HLA-presensitized donor. Transplantation 1992: 53: 659.
20. ALEGRE M, DEPIERREUX M, FLORQUIN S, et al. Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions. Transplant Proc 1990: 22: 1920.
21. FERRAN C, BLUESTONE J, BACH JF, CHATENOUD L. In vivo T-lymphocyte activation induced in mice following the injection of anti-CD3 monoclonal antibody. Transplant Proc 1990: 22: 1922.
22. REMICK DG, KUNKEL RG, LARRICK JW, KUNKEL SL. Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 1987: 56: 583.
23. ROSENBERG SA, LOTZE MT, MUTT LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987: 316: 889.
24. FERRAN C, SHEEHAN K, DY M, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T-cell activation. Eur J Immunol 1990: 20: 509.
25. HERBELIN A, CHATENOUD L, ROUX-LOMBARD P, et al. In vivo soluble tumor necrosis factor receptor release in OKT3-treated patients: differential regulation of TNF-sR55 and TNF-sR75. Transplantation 1995: 59: 1470.
26. BEMELMANS MHA, ABRAMOWICZ D, GOUMA DJ, GOLDMAN M. BUURMAN WA. In vivo T-cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice: effects of pentoxifylline. methylprednisolone, anti-TNF, and anti-IFN-γ antibodies. J Immunol 1994: 153: 499.